Article

Lensar announces FDA acceptance of 510(k) submission for adaptive cataract treatment system

The company notes that the system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools.

Lensar Inc. today announced that the FDA has accepted the 510(k) submission for its next-generation adaptive cataract treatment system (ALLY) for substantive review.

The submission seeks marketing clearance for the system and is the first stage of a planned, two step commercial release strategy. As part of this strategy, the company said in a news release that it plans to submit an additional 510(k) application seeking clearance for the phacoemulsification features within the integrated system later in 2022.

In the release, Nick Curtis, CEO of Lensar, noted that FDA acceptance for substantive review of the 510(k) submission for the surgical system marks an important milestone for the company and is the result of several years of diligent teamwork and focused effort on the part of its development team.

“We believe that, if ALLY is cleared by the FDA, this staged-approach would allow for an expeditious and efficient path to commercialization,” Curtis said in a statement. “The vast majority of cataract surgeons performing FLACS procedures rely on aging femtosecond lasers.”

Curtis also pointed out that system’s design includes a small footprint, enhanced ergonomics, superior imaging, dual-pulsed laser, and advanced astigmatism management tools which if cleared, company officials believe would set the new standard of femtosecond laser cataract technology.

“We believe ALLY has the potential to improve surgeon efficiencies, including optimizing FLACS procedures in any operating room, and to enable surgeons to deliver improved outcomes for patients,” he said in the statement. “We look forward to the FDA’s review of the 510(k).”

According to the news release, the company said it expects to launch the surgical system in the second half of 2022, if cleared.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
© 2025 MJH Life Sciences

All rights reserved.